 Shares of Buebird Bio Inc. BLUE, 7.90 jumped 12.1 in trading on Wednesday after the Food and Drug Administration approved the companys gene therapy as a treatment for betathalassemia in some adult and pediatric patients. Beta-thalassemia is a rare, genetic blood disease, and the patients who qualify for the treatment require regular red blood cell transfusions. 